## MarÃ-a D Lozano,, Miac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5648610/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessing the Relationship Between Lung Cancer Risk and Emphysema Detected on Low-Dose CT of the Chest. Chest, 2007, 132, 1932-1938.	0.8	385
2	Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors. Clinical Chemistry, 2015, 61, 297-304.	3.2	221
3	Women's Susceptibility to Tobacco Carcinogens and Survival After Diagnosis of Lung Cancer. JAMA - Journal of the American Medical Association, 2006, 296, 180-184.	7.4	220
4	Diagnostic Yield of Electromagnetic Navigation Bronchoscopy Is Highly Dependent on the Presence of a Bronchus Sign on CT Imaging. Chest, 2010, 138, 1316-1321.	0.8	214
5	Expression Analysis and Significance of PD-1, LAC-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clinical Cancer Research, 2019, 25, 4663-4673.	7.0	210
6	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine,the, 2018, 6, 771-781.	10.7	167
7	Early Lung Cancer Detection Using Spiral Computed Tomography and Positron Emission Tomography. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1378-1383.	5.6	163
8	Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer, 2003, 41, 131-143.	2.0	138
9	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1385-1393.	6.3	127
10	Mitogen-Activated Protein Kinase Phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients. Clinical Cancer Research, 2004, 10, 3639-3649.	7.0	125
11	CCR6 regulates EAE pathogenesis by controlling regulatory CD4 <sup>+</sup> Tâ€eell recruitment to target tissues. European Journal of Immunology, 2009, 39, 1671-1681.	2.9	114
12	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 2014, 9, e86263.	2.5	76
13	Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes. Oncologist, 2011, 16, 877-885.	3.7	75
14	Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2058-2065.	6.4	75
15	Immunocytochemistry in the differential diagnosis of serous effusions. Cancer, 2001, 93, 68-72.	4.1	69
16	Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins. International Journal of Surgical Pathology, 2000, 8, 133-144.	0.8	68
17	Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology, 2012, 30, 1129-1136.	1.6	63
18	TGFBI expression is associated with a better response to chemotherapy in NSCLC. Molecular Cancer, 2010, 9, 130.	19.2	61

#	Article	IF	CITATIONS
19	Cytology Smears in the Era of Molecular Biomarkers in Non–Small Cell Lung Cancer: Doing More With Less. Archives of Pathology and Laboratory Medicine, 2018, 142, 291-298.	2.5	60
20	Cribado de cáncer de pulmón: catorce años de experiencia del Programa Internacional de Detección Precoz de Cáncer de Pulmón con TBDR de Pamplona (P-IELCAP). Archivos De Bronconeumologia, 2015, 51, 169-176.	0.8	59
21	Comparative Study of Four Different Spherical Embolic Particles in an Animal Model: A Morphologic and Histologic Evaluation. Journal of Vascular and Interventional Radiology, 2008, 19, 1625-1638.	0.5	58
22	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	2.4	58
23	Large Cell Carcinoma of the Lung. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 383-392.	1.2	57
24	InÂVivo Evaluation of a New Embolic Spherical Particle (HepaSphere) in a Kidney Animal Model. CardioVascular and Interventional Radiology, 2008, 31, 367-376.	2.0	51
25	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on <scp>IL</scp> â€8. Journal of Pathology, 2021, 255, 190-201.	4.5	49
26	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation, 2016, 127, 153-168.	8.2	49
27	Assessment of a New ROS1 Immunohistochemistry CloneÂ(SP384)Âfor the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study. Journal of Thoracic Oncology, 2019, 14, 2120-2132.	1.1	48
28	Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. Clinical Cancer Research, 2011, 17, 4155-4166.	7.0	47
29	Global impact of the COVIDâ€19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathology, 2020, 128, 885-894.	2.4	47
30	ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. Cancer Cytopathology, 2017, 125, 817-830.	2.4	44
31	Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Molecular Biology, 2008, 9, 103.	3.0	40
32	Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget, 2018, 9, 6346-6355.	1.8	39
33	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	2.4	39
34	ld1 and ld3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. Journal of Translational Medicine, 2013, 11, 13.	4.4	38
35	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumor Biology, 2016, 37, 13687-13694.	1.8	37
36	Detection of EGFR Variants in Plasma. Journal of Molecular Diagnostics, 2018, 20, 483-494.	2.8	37

MarÃa D Lozano,, Miac

#	Article	IF	CITATIONS
37	EchoBrush may be superior to standard EUSâ€guided FNA in the evaluation of cystic lesions of the pancreas. Cancer Cytopathology, 2011, 119, 209-214.	2.4	35
38	Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT. Lung Cancer, 2016, 97, 81-86.	2.0	34
39	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. International Journal of Cancer, 2019, 145, 1991-2001.	5.1	32
40	Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence. Modern Pathology, 2020, 33, 2507-2519.	5.5	32
41	Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts. MAbs, 2014, 6, 1000-1012.	5.2	31
42	Programmed death–ligand 1 expression on direct Papâ€stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens. Cancer Cytopathology, 2019, 127, 470-480.	2.4	31
43	Fine-needle aspiration cytology and immunocytochemistry in the diagnosis of 24 gastrointestinal stromal tumors: A quick, reliable diagnostic method. Diagnostic Cytopathology, 2003, 28, 131-135.	1.0	29
44	A novel proteinâ€based prognostic signature improves risk stratification to guide clinical management in earlyâ€stage lung adenocarcinoma patients. Journal of Pathology, 2018, 245, 421-432.	4.5	29
45	Lung Cancer Screening: Fourteen Year Experience of the Pamplona Early Detection Program (P-IELCAP). Archivos De Bronconeumologia, 2015, 51, 169-176.	0.8	28
46	αCP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not Its Alternative Splice Variant αCP-4a, Is Underexpressed in Lung Cancer. Cancer Research, 2004, 64, 4171-4179.	0.9	27
47	Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2665-2672.	2.5	27
48	Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. BMC Genomics, 2010, 11, 352.	2.8	25
49	Assessment of EGFR and KRAS mutation status from FNAs and coreâ€needle biopsies of nonâ€small cell lung cancer. Cancer Cytopathology, 2015, 123, 230-236.	2.4	25
50	Survival with Parenchymal and Pleural Invasion of Non–Small Cell Lung Cancers Less than 30 mm. Journal of Thoracic Oncology, 2019, 14, 890-902.	1.1	25
51	Angiomyolipoma and PEComa Are Immunoreactive for MyoD1 in Cell Cytoplasmic Staining Pattern. Applied Immunohistochemistry and Molecular Morphology, 2003, 11, 156-160.	1.2	24
52	Molecular biomarkers in early stage lung cancer. Translational Lung Cancer Research, 2021, 10, 1165-1185.	2.8	23
53	Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLoS ONE, 2015, 10, e0119878.	2.5	23
54	Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clinica Chimica Acta, 2014, 429, 168-174.	1.1	20

#	Article	IF	CITATIONS
55	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Modern Pathology, 2013, 26, 171-181.	5.5	19
56	The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD. Clinical Imaging, 2021, 78, 136-141.	1.5	18
57	Molecular Profiling of Computed Tomography Screen-Detected Lung Nodules Shows Multiple Malignant Features. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 373-380.	2.5	17
58	TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal of Clinical Medicine, 2019, 8, 2134.	2.4	17
59	PD-L1 in Cytological Samples: A Review and a Practical Approach. Frontiers in Medicine, 2021, 8, 668612.	2.6	17
60	Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. Histology and Histopathology, 2008, 23, 33-40.	0.7	16
61	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory Journal, 2009, 34, 1477-1486.	6.7	15
62	Functional expression of CD137 (4-1BB) on T helper follicular cells. OncoImmunology, 2015, 4, e1054597.	4.6	15
63	A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer. Translational Research, 2021, 233, 77-91.	5.0	15
64	COVIDâ€19 pandemic impact on cytopathology practice in the postâ€lockdown period: An international, multicenter study. Cancer Cytopathology, 2022, 130, 344-351.	2.4	15
65	EUS-guided tissue acquisition in the study of the adrenal glands: Results of a nationwide multicenter study. PLoS ONE, 2019, 14, e0216658.	2.5	13
66	Solid pseudopapillary tumor of the pancreas (SPPT): Still an unsolved enigma. Revista Espanola De Enfermedades Digestivas, 2010, 102, 722-8.	0.3	13
67	Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma. European Journal of Dermatology, 2015, 25, 392-403.	0.6	12
68	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	2.8	12
69	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. Cancer Medicine, 2018, 7, 3474-3483.	2.8	11
70	CT screening for lung cancer: comparison of three baseline screening protocols. European Radiology, 2019, 29, 5217-5226.	4.5	11
71	Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Melanoma (MEL). Annals of Oncology, 2012, 23, ix361.	1.2	10
72	Variations in Molecular Profile in NSCLC Can Be Analyzed Using Cytological Samples. International Journal of Surgical Pathology, 2015, 23, 111-115.	0.8	10

MarÃa D Lozano,, Miac

#	Article	IF	CITATIONS
73	Characterization of Newly Detected Costal Pleura–attached Noncalcified Nodules at Annual Low-Dose CT Screenings. Radiology, 2021, 301, 724-731.	7.3	10
74	Towards the elimination of hepatitis C: implementation of reflex testing in Andalusia. Revista Espanola De Enfermedades Digestivas, 2020, 112, 515-519.	0.3	8
75	Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2014, 16, 362-373.	2.4	7
76	Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine (United States), 2019, 98, e16509.	1.0	6
77	Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis. Clinical Endocrinology, 2021, 94, 466-472.	2.4	6
78	Metastatic tumors in the pancreas: the role of endoscopic ultrasound-guided fine-needle aspiration. Revista Espanola De Enfermedades Digestivas, 2019, 111, 345-350.	0.3	6
79	FDG Uptake and the Diagnostic Yield of Transbronchial Needle Aspiration. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 7-14.	1.4	5
80	A comprehensive diagnosis of a desmoplastic small round cell tumor of unusual location based on fineâ€needle aspiration cytology: Report of a case arising in the parotid gland and review of the literature. Diagnostic Cytopathology, 2020, 48, 827-832.	1.0	5
81	Diagnostic accuracy of visual analysis versus dual time-point imaging with 18F-FDG PET/CT for the characterization of indeterminate pulmonary nodules with low uptake. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 155-160.	0.2	5
82	Gastrointestinal Endoscopic Ultrasoundâ€Guided Fineâ€Needle Aspiration for Assessing Suspected Deep Pelvic or Abdominal Recurrence in Gynecologic Cancer: A Feasibility Study. Journal of Ultrasound in Medicine, 2019, 38, 761-765.	1.7	4
83	Utilisation of cytological samples for multiplex immunofluorescence assay. Cytopathology, 2021, 32, 611-616.	0.7	4
84	Incidental lesions of the pancreas. A clinicopathological study of 100 cases surgically treated. Revista Espanola De Enfermedades Digestivas, 2019, 112, 85-89.	0.3	4
85	Teacher change: ideas emerging from a project for the teaching of university mathematics. Teaching in Higher Education, 2015, 20, 699-710.	2.6	3
86	Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS ONE, 2019, 14, e0215970.	2.5	3
87	Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results. Revista Espanola De Enfermedades Digestivas, 2010, 102, 314-20.	0.3	3
88	In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers. Annals of Oncology, 2017, 28, xi5.	1.2	2
89	Challenges of ICC and FISH in the Field of Targeted Therapies from Cell Block to Smears. Journal of Molecular Pathology, 2021, 2, 55-65.	1.2	1
90	Assessment of epidermal growth factor receptor (EGFR) and K-ras mutation status in cytologic stained smears of non-small cell lung cancer (NSCLC) patients Journal of Clinical Oncology, 2010, 28, 7560-7560.	1.6	1

## MarÃa D Lozano,, Miac

#	Article	IF	CITATIONS
91	Recommendations for optimizing the use of cytology in the diagnosis and management of patients with lung cancer. Revista Espanola De Patologia, 2022, , .	0.2	1
92	Feasibility and Usefulness of Determining EGFR and KRAS Mutations in Cytological Samples and CNB of NSCLC Using an Automated Real-Time PCR System. Annals of Oncology, 2012, 23, ix432.	1.2	0
93	P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients. Journal of Thoracic Oncology, 2018, 13, S553-S554.	1.1	0
94	The role of cytopathology practice and research in the development of personalized medicine in Iberoamerica. Diagnostic Cytopathology, 2020, 48, 819-820.	1.0	0
95	A Histological Study of the Barrier Effect of the Physis Against Metaphyseal Osteosarcoma. , 2009, , 71-78.		0
96	Inhibitor of differentiation-1 (Id1): A novel prognostic and predictive factor in lung adenocarcinoma (AC) Journal of Clinical Oncology, 2010, 28, 10611-10611.	1.6	0
97	Abstract 2251: High VEGFA pathway expression predicts good prognosis in stage I squamous cell carcinoma of the lung. , 2011, , .		0
98	Abstract 2219: Inhibitor of differentiation-1 is a novel prognostic factor among NSCLC patients with adenocarcinoma histology and contributes to therapy resistance. , 2011, , .		0
99	Feasability and reliabity of the assessment of BRAF and c-KIT mutations in cytologic samples from metastatic melanoma Journal of Clinical Oncology, 2011, 29, 8575-8575.	1.6	0
100	Spinal meningioma diagnosis based on transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). Revista Espanola De Enfermedades Digestivas, 2013, 105, 500-501.	0.3	0
101	Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers Journal of Clinical Oncology, 2014, 32, 8083-8083.	1.6	Ο
102	Abstract 954: Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib. , 2014, , .		0
103	Immunocytochemistry in the differential diagnosis of serous effusions. Cancer, 2001, 93, 68-72.	4.1	0